Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind double-dummy active-controlled study of HRG2005 inhalation in moderate to severe COPD
CTR20232867Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2023
- Countries
- 1
01
Overview
A Phase 2 trial of HRG2005 in chronic obstructive pulmonary disease (COPD), sponsored by Hengrui Therapeutics. Started Sep 2023; status: terminated.
02
Drugs
HRG2005
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20232867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232867.